Pfizer reported stronger-than-expected quarterly profits, driven by robust demand for its blood thinner, Eliquis.
Pfizer reported stronger-than-expected quarterly earnings, prompting an increase in the low end of its revenue guidance. The company has adjusted its full-year revenue expectation for Covid products to $4 billion, down from around $5 billion previously.
Pfizer reported stronger-than-expected earnings for the second quarter of 2026, leading the company to raise the midpoint of its sales forecast. The updated guidance reflects strong demand for older medicines, despite a reduction in revenue expectations for its Covid products, which were cut to $4 billion from around $5 billion.
Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase
European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application
Pfizer is paying $44 million to settle a Chantix lawsuit. See who could get money
Dow Jumps Over 700 Points; Pfizer Posts Upbeat Q2 Earnings
Pfizer Post Loss on Higher Revenue
Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings
Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
Pfizer Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials